Pretreatment with glycomacropeptide reduces allergen-sensitization, alleviates immediate cutaneous hypersensitivity and protects from anaphylaxis
Clinical and Experimental Immunology, 07/11/2012
Jimenez M et al. – The data demonstrate, for the first time, that the administration of glycomacropeptide (GMP) prevents from allergen–sensitization and reduces the severity of the early–phase reaction induced by antigen in cutaneous hypersensitivity and in anaphylaxis. GMP may be used as a novel prophylactic agent for the control of allergic diseases.